Literature DB >> 30190344

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Jyoti Naik1, Maria Themeli1, Regina de Jong-Korlaar1, Ruud W J Ruiter1, Pino J Poddighe2, Huipin Yuan3, Joost D de Bruijn3,4, Gert J Ossenkoppele1, Sonja Zweegman1, Linda Smit1, Tuna Mutis1, Anton C M Martens1, Niels W C J van de Donk1, Richard W J Groen5.   

Abstract

Entities:  

Year:  2018        PMID： 30190344      PMCID： PMC6395314          DOI： 10.3324/haematol.2018.192757

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.

Authors:  Karen L Bride; Tiffaney L Vincent; Soo-Yeon Im; Richard Aplenc; David M Barrett; William L Carroll; Robin Carson; Yunfeng Dai; Meenakshi Devidas; Kimberly P Dunsmore; Tori Fuller; Tina Glisovic-Aplenc; Terzah M Horton; Stephen P Hunger; Mignon L Loh; Shannon L Maude; Elizabeth A Raetz; Stuart S Winter; Stephan A Grupp; Michelle L Hermiston; Brent L Wood; David T Teachey
Journal:  Blood       Date:  2018-01-05       Impact factor: 22.113

Review 2.  Management of adults with T-cell lymphoblastic leukemia.

Authors:  David I Marks; Clare Rowntree
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

3.  Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Authors:  Antonella Antonelli; Willy A Noort; Jenny Jaques; Bauke de Boer; Regina de Jong-Korlaar; Annet Z Brouwers-Vos; Linda Lubbers-Aalders; Jeroen F van Velzen; Andries C Bloem; Huipin Yuan; Joost D de Bruijn; Gert J Ossenkoppele; Anton C M Martens; Edo Vellenga; Richard W J Groen; Jan Jacob Schuringa
Journal:  Blood       Date:  2016-10-12       Impact factor: 22.113

4.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Authors:  I S Nijhof; R W J Groen; H M Lokhorst; B van Kessel; A C Bloem; J van Velzen; R de Jong-Korlaar; H Yuan; W A Noort; S K Klein; A C M Martens; P Doshi; K Sasser; T Mutis; N W C J van de Donk
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

Review 5.  Immunotherapy in adult acute leukemia.

Authors:  Sabine Blum; Filipe Martins; Michael Lübbert
Journal:  Leuk Res       Date:  2017-06-29       Impact factor: 3.156

Review 6.  Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.

Authors:  Noortje van Gils; Han J M P Verhagen; Linda Smit
Journal:  Exp Hematol       Date:  2017-04-27       Impact factor: 3.084

Review 7.  CD38 antibodies in multiple myeloma: back to the future.

Authors:  Niels W C J van de Donk; Paul G Richardson; Fabio Malavasi
Journal:  Blood       Date:  2017-11-08       Impact factor: 22.113

8.  Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

Authors:  Mya S Thein; William B Ershler; Ahmedin Jemal; Jerome W Yates; Maria R Baer
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

9.  Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.

Authors:  Han J M P Verhagen; Marjon A Smit; Arjo Rutten; Fedor Denkers; Pino J Poddighe; Pauline A Merle; Gert J Ossenkoppele; Linda Smit
Journal:  Blood       Date:  2015-11-18       Impact factor: 22.113

10.  All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia.

Authors:  Tetsumi Yoshida; Keichiro Mihara; Yoshifumi Takei; Kazuyoshi Yanagihara; Takanori Kubo; Joyeeta Bhattacharyya; Chihaya Imai; Tatsuji Mino; Yoshihiro Takihara; Tatsuo Ichinohe
Journal:  Clin Transl Immunology       Date:  2016-12-09
View more
  34 in total

1.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

2.  IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells.

Authors:  Noortje van Gils; Han J M P Verhagen; Arjo Rutten; Renee X Menezes; Mei-Ling Tsui; Eline Vermue; Esmée Dekens; Fabio Brocco; Fedor Denkers; Floortje L Kessler; Gert J Ossenkoppele; Jeroen J W M Janssen; Linda Smit
Journal:  Blood Adv       Date:  2020-12-22

Review 3.  CAR T cells for other pediatric non-B-cell hematologic malignancies.

Authors:  Adam J Lamble; Rebecca Gardner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 4.  Beyond CD19 CAR-T cells in lymphoma.

Authors:  Wingchi K Leung; Adanma Ayanambakkam; Helen E Heslop; LaQuisa C Hill
Journal:  Curr Opin Immunol       Date:  2021-11-17       Impact factor: 7.486

Review 5.  Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche.

Authors:  Rebecca S Maynard; Charlotte Hellmich; Kristian M Bowles; Stuart A Rushworth
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

6.  Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia.

Authors:  Jayna J Mistry; Charlotte Hellmich; Amelia Lambert; Jamie A Moore; Aisha Jibril; Angela Collins; Kristian M Bowles; Stuart A Rushworth
Journal:  Biomark Res       Date:  2021-05-13

7.  Harnessing immunotherapy for pediatric T-cell malignancies.

Authors:  Caroline Diorio; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2020-02-27       Impact factor: 5.124

8.  Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.

Authors:  Prashant Ramesh Tembhare; Harshini Sriram; Twinkle Khanka; Gaurav Chatterjee; Devasis Panda; Sitaram Ghogale; Yajamanam Badrinath; Nilesh Deshpande; Nikhil V Patkar; Gaurav Narula; Bhausaheb Bagal; Hasmukh Jain; Manju Sengar; Navin Khattry; Shripad Banavali; Sumeet Gujral; Papagudi G Subramanian
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 9.  The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases.

Authors:  Kelly A Hogan; Claudia C S Chini; Eduardo N Chini
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 8.786

Review 10.  NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer.

Authors:  Valentina Audrito; Antonella Managò; Federica Gaudino; Leonardo Sorci; Vincenzo Gianluca Messana; Nadia Raffaelli; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.